50+ Leading Acute Kidney Injury Pipeline Companies are working to improve the treatment landscape

50+ Leading Acute Kidney Injury Pipeline Companies are working to improve the treatment landscape

DelveInsight’s, “Acute Kidney Injury Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Acute Kidney Injury pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Acute Kidney Injury pipeline report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Acute Kidney Injury NDA approvals (if any), and product development activities comprising the technology, Acute Kidney Injury collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Acute Kidney Injury Pipeline Insight Report

 

  • DelveInsight’s Acute Kidney Injury Pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Acute Kidney Injury treatment.
  • The leading Acute Kidney Injury companies include Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, Exponential Biotherapies, Astellas Pharma, Amniotics, Mission Therapeutics, Bessor pharma, Kantum Pharma, Nephraegis Therapeutics, Vasomune, Unicycive, ABIONYX and others are developing novel drug candidates to improve the Acute Kidney Injury treatment landscape.
  • Promising Acute Kidney Injury pipeline therapies in various stages of development include bRESCAP, ANG-3777, EA-230, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), UMC 119 06, Kidney specific amniotic mesenchymal stem cell therapy, RMC 035, SBI-101, QPI-1002, RMC035, MIB-626, RBT-9, Recombinant human alkaline phosphatase, XRx-101, SUL-138, UNI494, Timbetasin, and others.
  • The Acute Kidney Injury companies and academics that are working to assess challenges and seek opportunities that could influence Acute Kidney Injury R&D. The Acute Kidney Injury pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

 

To explore more information on the latest breakthroughs in the Acute Kidney Injury Pipeline treatment landscape of the report, click here @ Acute Kidney Injury Pipeline Outlook

 

Acute Kidney Injury Overview

Acute kidney injury (AKI), also known as acute renal failure (ARF), is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in your blood and makes it hard for your kidneys to keep the right balance of fluid in your body. AKI can also affect other organs such as the brain, heart, and lungs. Acute kidney injury is common in patients who are in the hospital, in intensive care units, and especially in older adults. There are rarely any symptoms until the condition has progressed to a late stage. However, if there are symptoms, the most common one is a decrease in urine output.

 

Recent Developmental Activities in the Acute Kidney Injury Pipeline

  • In March 2022, at the 27th International Conference on Advances in Critical Care Nephrology, AM-Pharma will deliver an overview of the current Phase III REVIVAL study.
  • In September 2021, AM-Pharma agreed to an exclusive licensing deal with Kyowa Kirin giving Kyowa Kirin the rights to develop and sell ilofotase alfa in Japan.
  • In December 2021, Researchers at the University of Groningen, the Netherlands and their collaborators, reported a lead compound for the treatment of Acute Kidney Injury (AKI). A new 6-chromanol-derived compound named SUL-138 being developed by Sulfateq BV has shown promise in animal models at treating acute kidney injury.
  • In February 2022, Renibus Therapeutics completed a USD 15 million extension as part of its Series A financing, led by family offices specializing in biotech investments, closing the round at USD 35 million. Proceeds from the financing will be used to advance Renibus’ pipeline, including the company’s lead candidates, RBT-1 for the prevention of acute kidney injury.
  • In May 2021, Nephraegis Therapeutics, developing NPH-022 to prevent and treat Acute Kidney Injury (AKI) launched with a seed investment from Xontogeny, LLC to advance their lead compound through critical preclinical work.
  • In December 2021, Altasciences has been chosen by XORTX Therapeutics Inc. to conduct a pharmacokinetic bridging study in support of the XRx-008 program for autosomal dominant polycystic kidney disease (ADPKD), and XRx-101 for acute kidney injury associated with COVID-19.
  • In June 2021, KBI Biopharma entered into a manufacturing agreement with AM Pharma, particularly concerning to AM Pharma’s recAP program potentially being investigated for the treatment of sepsis-associated acute kidney injury.

 

Request a sample and discover the recent advances in Acute Kidney Injury Ongoing Clinical Trial Analysis and Medications, click here @ Acute Kidney Injury Treatment Landscape

 

Acute Kidney Injury Emerging Drugs Profile

 

RMC-035: GUARD THERAPEUTICS

Guard Therapeutics is developing RMC-035 (ROSgard), a biological drug candidate that utilizes one of the body’s most powerful and universal protections against oxidative stress. RMC-035 is naturally designed to “target” the kidneys, allowing RMC-035 to be present when the kidneys are attacked by oxidative stress. Treatment with RMC-035 has the potential to save lives and prevent the risk of both acute and chronic kidney damage with subsequent serious consequences due to impaired kidney function, such as life-sustaining dialysis treatment. Currently, it is in Phase II stage of clinical trial evaluation to treat Acute Kidney Injury.

 

RBT-1: Rénibus Therapeutics

Rénibus’ lead product, RBT-1, is a novel pharmacologic intervention combining stannous protoporphyrin and iron sucrose, induces a preconditioning protective effect on the kidney and other organs, upregulating production of protective proteins to prevent post-operative complications following cardiothoracic surgery, including AKI, days in the ICU, time on ventilator, and hospital readmission rates. Pre-clinical and Phase I development is complete, and RBT-1’s Phase II trial a Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Effect of RBT-1 on Preconditioning Response Biomarkers in Subjects Undergoing Coronary Artery Bypass Graft (CABG) and/or Cardiac Valve Surgery (The START Study) was initiated in April 2021 and is expected to be completed in Q4 2022. A pre-specified interim analysis was conducted following the enrollment of the first 60 patients, yielding statistically significant results in both the primary and several secondary endpoints.

 

Acute Kidney Injury Pipeline Therapeutics Analysis

There are approx. 30+ key companies which are developing the therapies for Acute Kidney Injury. The companies which have their Acute Kidney Injury drug candidates in the most advanced stage, i.e. phase II include, GUARD THERAPEUTICS.

 

 For further information, refer to the detailed Acute Kidney Injury Unmet Needs, Acute Kidney Injury Market Drivers, and Market Barriers, click here for Acute Kidney Injury Ongoing Clinical Trial Analysis

 

Scope of the Acute Kidney Injury Pipeline Report

 

  • Coverage: Global
  • Acute Kidney Injury Companies: Atox Bio, AM Pharma Holding, Quark-Pharmaceuticals, LG Chem, Pharming Group, Angion Biomedica, Elysium Health, Sentien Biotechnologies, Pharmazz, Arch Biopartners, Guard Therapeutics, RegeneRx Biopharmaceuticals, Cerenis Therapeutics Alloksys, Vifor Pharma, Exponential Biotherapies, Astellas Pharma, Pharming Technologies, and others.
  • Acute Kidney Injury Pipeline Therapies: bRESCAP, ANG-3777, EA-230, Ilofotase alfa, ASP1128, Ruconest (Conestat alfa), and others.
  • Acute Kidney Injury Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

 

Dive deep into rich insights for drugs for Acute Kidney Injury Market Drivers and Acute Kidney Injury Market Barriers, click here @ Acute Kidney Injury Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Acute Kidney Injury Executive Summary
  3. Acute Kidney Injury: Overview
  4. Acute Kidney Injury Pipeline Therapeutics
  5. Acute Kidney Injury Therapeutic Assessment
  6. Acute Kidney Injury – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name: Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. RMC-035: GUARD THERAPEUTICS
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. SBI 101 – Sentien Biotechnologies
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. ILB-202: ILIAS Biologics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Acute Kidney Injury Key Companies
  21. Acute Kidney Injury Key Products
  22. Acute Kidney Injury- Unmet Needs
  23. Acute Kidney Injury- Market Drivers and Barriers
  24. Acute Kidney Injury- Future Perspectives and Conclusion
  25. Acute Kidney Injury Analyst Views
  26. Acute Kidney Injury Key Companies
  27. Appendix

 

Got Queries? Find out the related information on Acute Kidney Injury Mergers and acquisitions, Acute Kidney Injury Licensing Activities @ Acute Kidney Injury Emerging Drugs, and Recent Trends

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services


Posted

in

by

Tags: